Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 14 of 14 entries
Sorted by: Best Match Show Resources per page
On the robustness of generalization of drug-drug interaction models.

BMC bioinformatics

Kpanou R, Osseni MA, Tossou P, Laviolette F, Corbeil J.
PMID: 34607569
BMC Bioinformatics. 2021 Oct 04;22(1):477. doi: 10.1186/s12859-021-04398-9.

BACKGROUND: Deep learning methods are a proven commodity in many fields and endeavors. One of these endeavors is predicting the presence of adverse drug-drug interactions (DDIs). The models generated can predict, with reasonable accuracy, the phenotypes arising from the...

Cite
Kpanou R, Osseni MA, Tossou P, et al. On the robustness of generalization of drug-drug interaction models. BMC Bioinformatics. 2021;22(1):477doi: 10.1186/s12859-021-04398-9.
Kpanou, R., Osseni, M. A., Tossou, P., Laviolette, F., & Corbeil, J. (2021). On the robustness of generalization of drug-drug interaction models. BMC bioinformatics, 22(1), 477. https://doi.org/10.1186/s12859-021-04398-9
Kpanou, Rogia, et al. "On the robustness of generalization of drug-drug interaction models." BMC bioinformatics vol. 22,1 (2021): 477. doi: https://doi.org/10.1186/s12859-021-04398-9
Kpanou R, Osseni MA, Tossou P, Laviolette F, Corbeil J. On the robustness of generalization of drug-drug interaction models. BMC Bioinformatics. 2021 Oct 04;22(1):477. doi: 10.1186/s12859-021-04398-9. PMID: 34607569; PMCID: PMC8489092.
Copy Download .nbib Format: NLM
Classification of drugs for evaluating drug interaction in drug development and clinical management.

Drug metabolism and pharmacokinetics

Maeda K, Hisaka A, Ito K, Ohno Y, Ishiguro A, Sato R, Nagai N.
PMID: 34666290
Drug Metab Pharmacokinet. 2021 Dec;41:100414. doi: 10.1016/j.dmpk.2021.100414. Epub 2021 Jul 08.

During new drug development, clinical drug interaction studies are carried out in accordance with the mechanism of potential drug interactions evaluated by in vitro studies. The obtained information should be provided efficiently to medical experts through package inserts and...

Cite
Maeda K, Hisaka A, Ito K, et al. Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug Metab Pharmacokinet. 2021;41:100414doi: 10.1016/j.dmpk.2021.100414.
Maeda, K., Hisaka, A., Ito, K., Ohno, Y., Ishiguro, A., Sato, R., & Nagai, N. (2021). Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug metabolism and pharmacokinetics, 41100414. https://doi.org/10.1016/j.dmpk.2021.100414
Maeda, Kazuya, et al. "Classification of drugs for evaluating drug interaction in drug development and clinical management." Drug metabolism and pharmacokinetics vol. 41 (2021): 100414. doi: https://doi.org/10.1016/j.dmpk.2021.100414
Maeda K, Hisaka A, Ito K, Ohno Y, Ishiguro A, Sato R, Nagai N. Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug Metab Pharmacokinet. 2021 Dec;41:100414. doi: 10.1016/j.dmpk.2021.100414. Epub 2021 Jul 08. PMID: 34666290.
Copy Download .nbib Format: NLM
Showing 13 to 14 of 14 entries